Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | NAMPT | P43490 | 3/20 | 0.55 |
| ▸ | MTTP | P55157 | 7/20 | 0.52 |
| ▸ | APOB | P04114 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081600 | 0.90 | SORT1 (0.53) | KDRNAMPTMTTPAPOBALDH1A1 | |
| SCHEMBL6788420 | 0.89 | MTTP (0.57) | KDRNAMPTMTTPAPOBALDH1A1 | |
| SCHEMBL6794043 | 0.88 | SMO (0.61) | KDRMTTPAPOBGAASMO | |
| SCHEMBL6792347 | 0.83 | NAMPT (0.54) | KDRNAMPTMTTPAPOBHDAC1 | |
| SCHEMBL6796384 | 0.82 | SMO (0.55) | KDRMTTPAPOBGAASMO | |
| SCHEMBL6799294 | 0.82 | KMT2A (0.56) | KDRMTTPAPOBALDH1A1SMO | |
| SCHEMBL7605521 | 0.82 | RXFP1 (0.55) | KDRNAMPTMTTPAPOBABL1 | |
| SCHEMBL3729112 | 0.82 | NR1H4 (0.58) | MTTPAPOBALDH1A1 | |
| SCHEMBL6794895 | 0.82 | KDR (0.57) | KDRMTTPAPOBALDH1A1MAPT | |
| SCHEMBL6791890 | 0.81 | MTTP (0.59) | KDRMTTPAPOBGAASMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | KDR 3180/4885NAMPT 1407/4885MTTP 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.